John Quigley, Ph.D
Associate Professor of Medicine


Institute Name Degree Year
National Cancer Institute of Canada Postdoctoral Fellowship, Terry Fox Laboratory, Vancouver, BC: R. K. Humphries Ph.D 1994-1996
Department of Medicine, Division of Hematology, University of Washington M.D 1996-1998


Dr. Quigley received his medical degree from the University College Dublin in Dublin, Ireland. He then completed initial internal medicine training in Dublin and London, he moved to Canada for an internal medicine residency at the University of Saskatchewan in Saskatoon, followed by a clinical hematology fellowship at McMaster University in Hamilton, Ontario. He also completed additional training in hematology/oncology at the University of Washington in Seattle, Washington. Before coming to the University of Illinois, Dr. Quigley served as visiting BMT physician at the Fred Hutchinson Cancer Research Center, Seattle, WA

Research Interest

  1. To investigate regulation of the expression of the human cell-surface heme transporter (FLVCR). For the last 10+ years he has worked in the field of heme biology, focusing on the function of FLVCR, a retroviral receptor that impairs erythropoiesis in cats, causing a severe anemia. In 2004, they described the heme export function of the human ortholog, the first mammalian heme transporter identified. In 2008 the conditional knockout of the murine FLVCR ortholog was published, demonstrating that FLVCR function is required to allow definitive erythropoiesis and that its absence disturbs systemic iron homeostasis. Since 2007 they have studied the protein trafficking of FLVCR, which is regulated by a tyrosine phosphatase, PTPN3 (publication submitted). In addition, they noted that motifs in the N-terminus of this transporter are important for cell surface expression and are analyzing their importance.
  2. A more recent focus in the lab is the role of heme and heme transports in the basic biology of Anopheles the most important vectors for transmission of Plasmodium spp., and thus malaria. They have shown that expression of the mosquito orthologs (an FLVCR) are up regulated robustly in response to a blood meal (hematophagy) and export heme in heterologous cells. The insect midgut is exposed to high levels of heme; thus, dysregulation of an FLVCR heme export may impact midgut production of reactive oxygen species (ROS), which are deleterious to Plasmodium transmission. The lab has knocked down the gene in adult mosquitoes; examining ROS generation and Plasmodium transmission. They developed a close collaboration with colleagues at Loyola University and at the Laboratory for Vector Research at the NIAID (NIH, Bethesda, MD) to examine an FLVCR in more detail. We believe our studies will help elucidate the role of an FLVCR in protecting mosquitoes from heme toxicity and determine whether an FLVCR dysfunction impacts transmission of the malaria parasite at its weakest point, i.e., plasmodium (ookinete) invasion of the mosquito midgut. Improved understanding of heme transport in hematophagous mosquitoes, an understudied topic, may reveal novel approaches to control malaria, a neglected disease. Successful demonstration that impairment of an FLVCR function prevents Plasmodium transmission would provide a rationale to develop small molecule inhibitors of an FLVCR function and/or a transmission-blocking vaccine. Notably, FLVCR orthologs are also present in the genomes of numerous insect vectors, including those that transmit prevalent diseases such as dengue fever and West Nile virus. The lab envisions that knowledge gained from their research may be applicable more generally to hematophagous disease-bearing insects.

Scientific Activities

Professional Memberships
  • American Society of Gene and Cell Therapy, Associate Member, 1998-2002
  • American Society of Hematology, Member, 1998-present
  • Children’s Oncology Group, Member, 2008-present
  • Eastern Cooperative Oncology Group, Member, 2008-present
  • The Alliance for Clinical Trials in Oncology Foundation (formerly CALGB), Member, 2006-present
Honors and Awards
  • National Cancer Institute of Canada Postdoctoral Fellowship, 1994-1996
  • Plenary Session presentation, ASH Annual Meeting, 2010


Books and Monographs
  1. The Birth, Life, and Death of Red Blood Cells: Erythropoiesis, The Mature Red Blood Cell, and Cell Destruction. Quigley, JG, Glader, B, and Means, RT. In: Wintrobe’s Clinical Hematology, (Chapter 6, pp84-124), 13th edition, (2014). Editors: Greer, JP et al. (14th edition now in review)

Refereed Journal Articles
  1. Sweiss K, Quigley JG, Oh A, Lee J, Ye R, Rondelli D, Patel P (2017)A novel drug interaction between busulfan and blinatumomab. J Oncol Pharm Pract
  2. Vargas A, Dixit KS, Quigley JG, Testai FD (2016) Spinal cord and cranial Bing-Neel Syndrome complicated by cerebral ischemia: A case report. J Neurol Sci 366: 44-46.
  3. Khan I, Shergill A, Saraf SL, Chen YF, Patel PR, Quigley JG, Peace D, Gordeuk VR, Hoffman R, Rondelli D (2016) Outcome Disparities in Caucasian and Non-Caucasian Patients with Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk 16: 350-357.
  4. Altman IA, Kleinfelder RE, Quigley JG, Ennis WJ, Minniti CP (2016) A treatment algorithm to identify therapeutic approaches for leg ulcers in patients with sickle cell disease. Int Wound J 13: 1315-1324.
  5. Saraf SL, Oh AL, Patel PR, Jalundhwala Y, Sweiss K, Koshy M, Campbell-Lee S, Gowhari M, Hassan J, Peace D, Quigley JG, Khan I, Molokie RE, Hsu LL, Mahmud N, Levinson DJ, Pickard AS, Garcia JG, Gordeuk VR, Rondelli D (2016) Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. Biol Blood Marrow Transplant. 22: 441-448.
  6. Yu Hou Y, Li W, Sheng Y, Wu W, Huang Y, Peace D, Quigley JG, Zhao Y, Qian Z (2015) The transcription factor Foxm1 is essential for the quiescence and maintenance of hematopoietic stem cells. Nat Immunol. 16: 801-808.
  7. Patel P, Aydogan B, Koshy M, Mahmud D, Oh A, Saraf SL, Quigley JG, Khan I, Sweiss K, Mahmud N, Peace DJ, Demasi V, Awan AM, Weichselbaum RR, and Rondelli D (2014) Combination of Linear Accelerator Based Intensity Modulated Total Marrow Irradiation and Myeloablative Fludarabine/Busulfan: A Phase I Study. Biol Blood Marrow Transplant 20:2034-2041.
  8. Mahmud N, Petro B, Baluchamy S, Xinmin Li, Taioli S, Lavelle D, Quigley J, Suphangul M, Araki H (2014) Differential effects of epigenetic modifiers on the expansion and maintenance of human cord blood stem/progenitor cells. Biol Blood Marrow Transplant. 20: 480-489.
  9. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, et al. (2013) The Concise Guide to Pharmacology 2013/14: overview. Br J Pharmacol. 170: 1449-1458.
  10. Khan AA, Jeong J, Walker MJ, Chishti, AH and Quigley, JG. PTPN3  A non-receptor protein tyrosine phosphatase, interacts with and regulates the localisation and activity of the mammalian haem exporter FLVCR. Biochim Biophys Acta MCR (submitted)
  11. Khan AA and Quigley JG (2013) SLC48 and SLC49 Heme and FLVCR-Related Transporter Families. Molecular Aspects of Medicine. 2-3: 669-682.
  12. Saraf, SL, Patel, P, Ozer, H, Peace,DJ, Quigley, JG, Mahmud, N, and Rondelli D (2013) Improved outcomes with novel agents and auto-SCT for multiple myeloma in African-American patients. Bone Marrow Transplant 48: 319-20.
  13. Khan AA and Quigley JG (2011) Control of intracellular heme levels: Heme transporters and heme oxygenases. Biochim Biophys Acta  5: 668-82.
  14. Beri R, Chunduri S, Sweiss K, Peace,DJ, Mactal-Haaf C, Dobogai LC, Shord S, Quigley JG, Chen YH, Mahmud N. and Rondelli D (2010) Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative Flu Bu conditioning regimen. Bone Marrow Transplant (45): 249-53.
  15. Aakalu, VK, Sepahdari, AR, Quigley, JG and Gilbert, M (2009) Ocular presentation of precursor B-cell lymphoblastic lymphoma and optic neuropathy in an adult. NeuroOphthalmology 33: 188-94.
  16. Chi Y, Lindgren V, Quigley S, and Gaitonde S (2008) Acute myelogenous leukemia with t (6;9)(p23;q34) and marrow basophilia: An overview. Arch Pathol Lab Med (132): 1835-37.
  17. Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH, Mahmud N, Hurter E, Beri R, and Rondelli D (2008) Fludarabine/i.v. BU conditioning regimen: Myeloablative, reduced intensity or both. Bone Marrow Transplant 41: 935-40.
  18. Keel, SB, Doty, RT, Yang, Z, Quigley, JG, Chen, J, Knoblaugh, S, Kingsley, PD, De Domenico, I, Vaughn, MB, Kaplan, J, Palis, J, and Abkowitz, JL (2008) A heme export protein is required for red cell differentiation and iron homeostasis. Science (319): 825-28.
  19. Chunduri S., Dobogai LC, Peace D, Saunthararajah Y, Chen HY, Mahmud N, Quigley J, Hoffman R, Jessop E, Beri R., and Rondelli D (2006) Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant (38): 477-82.
  20. M. Lee Lucas, Nancy E. Seidel, Christopher D. Porada, John G. Quigley, Stacie M. Anderson, Harry L. Malech, Janis L. Abkowitz, Esmail D. Zanjani, and David M. Bodine (2005) Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes. Blood (106): 51-58.
  21. Quigley, JG, Gazda, H, Yang, Z, Ball, S, Sieff, CA and Abkowitz, JL (2005) Investigation of a putative role for FLVCR, a cytoplasmic heme exporter, in DiamondBlackfan anemia. Blood Cells Mol Dis 35: 189-92.
  22. Quigley JG, Worthington MT, Yang Z, Sabo KM, Sabath DF, Berg CL, Sassa, S Wood BL and Abkowitz JL (2004) Identification of a human heme exporter that is essential for erythropoiesis. Cell 118: 757-66.
  23. Lipovich L, Hughes AL, Abkowitz JL, King MC and Quigley JG (2002) Genomic structure and evolutionary context of the human feline leukemia virus subgroup C receptor (hFLVCR) gene: evidence for block duplications and de novo gene formation within duplicons of the hFLVCR locus. Gene 286: 203-13.
  24. Quigley JG, Burns CC, Anderson MM, Lynch ED, Sabo KM, Overbaugh J and Abkowitz JL (2000) Cloning of the cellular receptor for feline leukemia virus subgroup C (FeLV–C), a retrovirus that induces red cell aplasia. Blood 95: 1093-99.
  25. Neame PB, Soamboonsrup P, Quigley JG and Pewarchuk W (1994) The use of monoclonal antibodies and immune markers in the diagnosis, prognosis, and therapy of acute leukemia. Transfusion Med Rev 8: 59-75.
Other Works, Publications and (selected) Abstracts

Oral Presentations

  1. Jeong, JJ, Khan AA, Lamm M, Kanzok S and Quigley JG (2010) Anopheline orthologs of the human erythroid heme exporter, FLVCR, export heme: Potential targets to inhibit Plasmodium transmission. ASH Annual Meeting 2010, Plenary Session presentation. Blood 116: 2.
  2. Araki H, Baluchamy S, Petro B, Baig MS, Suhangul M, Quigley JG, Katayama N and Mahmud N (2010) Valproic acid results in maintenance but not expansion of transplantable hematopoietic stem cells from human umbilical cord blood. ASH Annual Meeting 2010, Simultaneous Session oral presentation. Blood 116: 827.
  3. Khan AA, Jeong J, Walker MJ, Chishti, AH and Quigley, JG (2009) PTPN3, a tyrosine phosphatase, regulates expression of the erythroid heme transporter, FLVCR. ASH Annual Meeting 2009, Simultaneous Session oral presentation. Blood 114: 322.
  4. Petro B, Araki H, Quigley JG, Rondelli D, and Mahmud N (2009) In vivo treatment with chromatin modifying agents dramatically increases hematopoietic stem cell numbers. ASH Annual Meeting 2009, Simultaneous Session oral presentation. Blood 114: 156.
  5. Khan AA. and Quigley JG (2009) Regulation of FLVCR, the erythroid heme transporter. Invited presentation, Red Cell Club Annual Meeting, Yale University.
  6. Yang ZT, Quigley JG, Cohen ML, Sabo KM, Wood BF, Sabath DF and Abkowitz JL (2002) Studies of FLVCR regulation in K562 cells demonstrate its importance in erythropoiesis. ASH Annual Meeting 2002, Simultaneous Session oral presentation. Blood 100: 656-57.

Autoimmune Journal Flyer